ASTRAZENECA PHARMACEUTICALS v. APOTEX CORP., 2011-1182 (Fed. Cir. 5-10-2011)
ASTRAZENECA PHARMACEUTICALS LP, ASTRAZENECA AB, IPR PHARMACEUTICALSINC., AND THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Plaintiffs-Appellants,v. APOTEX CORP., Defendant-Appellee, and AUROBINDO PHARMA LIMITED,Defendant-Appellee, and COBALT PHARMACEUTICALS INC. AND COBALTLABORATORIES INC., Defendants-Appellees, and GLENMARK GENERICS INC. USA,Defendant-Appellee, and MYLAN PHARMACEUTICALS INC., Defendant-Appellee,and PAR PHARMACEUTICALS, INC.,Page 2Defendant-Appellee, and SUN PHARMACEUTICAL INDUSTRIES,LTD., Defendant-Appellee, and TEVA PHARMACEUTICALS USA, INC.,Defendant-Appellee, and TORRENT PHARMA INC. AND TORRENTPHARMACEUTICALS LTD., Defendants.
Nos. 2011-1182, 2011-1183, 2011-1184, 2011-1185, 2011-1186, 2011-1187,2011-1188, 2011-1189, 2011-1190.United States Court of Appeals, Federal Circuit.
May 10, 2011.
[EDITOR'S NOTE: This case is unpublished as indicated by the issuing court.]
Appeals from the United States District Court for the District of Delaware in case nos. 10-CV-0338, 10-CV-0339, 10-CV-0340, 10-CV-0341, 10-CV-0342, 10-CV-0343, 10-CV-0345, 10-CV-0346, and 10-CV-0584, Judge Robert B. Kugler.
ON MOTION ORDER
Upon consideration of the motion to withdraw Dutch Chung as principal counsel for Par Pharmaceuticals, Inc.,
IT Is ORDERED THAT:
(1) The motion is granted.Page 3
(2) New principal counsel for Par Pharmaceuticals, Inc. must promptly enter a new entry of appearance.Page 1